+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Pro or con the phenotyping/genotyping of patients treated by 5-Fluorouracil to prevent adverse drug reactions?

Pro or con the phenotyping/genotyping of patients treated by 5-Fluorouracil to prevent adverse drug reactions?

Therapie 62(2): 105-109

5-fluorouracil, (5-FU) is an antimetabolite used in many types of cancers. It has a narrow therapeutic index. More than 80% of administered 5-FU is detoxified in 5-fluoro-5,6-dihydrouracil (5-FUH2) by an enzyme: dihydropyrimidine dehydrogenase (DPD). Half life increased with DPD deficiency. Thus, patients presenting a partial or profound DPD deficiency have an increased risk of severe or lethal toxicity. DPD deficiency was estimated between 3 to 5% in the normal population. Different approaches have been developed: Pharmacogenetic on the DPD gene or pharmacologic measuring DPD activity. More than 30 mutations have been reported on this gene. The more common mutation is the slice-site mutation IVS14+1G>A. Analysis of the various mutations allowed to identify a population at risk with a DPD deficiency. DPD activity is determined in peripheral blood mononuclear cells. This assay offers the capability of identifying individuals who are completely deficient in DPD activity and those who are partially deficient. Assays to detect DPD deficiency are not used as a screening test to prevent 5-FU toxicity.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 055187759

Download citation: RISBibTeXText

PMID: 17582310

DOI: 10.2515/therapie:2007025

Related references

Cost-effectiveness Analysis for Genotyping before Allopurinol Treatment to Prevent Severe Cutaneous Adverse Drug Reactions. Journal of Rheumatology 44(6): 835-843, 2017

Debrisoquine oxidation phenotyping and adverse drug reactions utility of phenotyping in general hospital admissions. British Journal of Clinical Pharmacology 20(3): 254P-255P, 1985

High-resolution HLA genotyping and severe cutaneous adverse reactions in lamotrigine-treated patients. Pharmacogenetics and Genomics 19(9): 661-665, 2009

Genotyping of the N-acetyltransferase2 polymorphism in the prediction of adverse drug reactions to isoniazid in Japanese patients. Drug Metabolism and Pharmacokinetics 17(4): 357-362, 2004

The Beers List as an aid to prevent adverse drug reactions in elderly patients. Nederlands Tijdschrift Voor Geneeskunde 149(38): 2099-2103, 2005

Characteristics associated with ability to prevent adverse drug reactions in hospitalized patients. Pharmacotherapy 18(6): 1284-1289, 1998

Dihydropyrimidine Dehydrogenase Genotyping and Phenotyping for 5- Fluorouracil Dysmetabolism: Moving Towards Personalized Chemotherapy in Patients with Cancer. Current Pharmacogenomics and Personalized Medicine 7(4): 275-283, 2009

Characteristics associated with ability to prevent adverse drug reactions in hospitalized patients--a comment. PharmacoTherapy 19(10): 1185-6; Discussion 1186-7, 1999

Phenotyping Adverse Drug Reactions: Statin-Related Myotoxicity. AMIA Joint Summits on Translational Science Proceedings. AMIA Joint Summits on Translational Science 2015: 466-470, 2015

Genotyping of drug targets: a method to predict adverse drug reactions?. Drug Safety 25(8): 553-560, 2002

Percentage of patients with preventable adverse drug reactions and preventability of adverse drug reactions--a meta-analysis. Plos One 7(3): E33236, 2012

Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study. BMJ 351: H4848, 2015

Genotyping as a tool to predict adverse drug reactions. Current Topics in Medicinal Chemistry 4(13): 1411-1421, 2004

Monitoring of patients treated with antihypertensive therapy for adverse drug reactions. Adverse Drug Reaction Bulletin &na;(261): 1003-1006, 2010

Adverse Drug reactions in an Ageing PopulaTion (ADAPT) study protocol: a cross-sectional and prospective cohort study of hospital admissions related to adverse drug reactions in older patients. BMJ Open 7(6): E017322, 2018